After exclusion of individuals with prior neoplasms and type 1 diabetes, and after ensuring hypoglycemic medication use around diagnosis, the final analytical sample comprised 235,955 GLP-1 RA users and 2,365,766 non-users. The gene discussed is GLP1R; the disease is neoplasm.